Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
January 5, 2023Business Services
Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
FDA accepts application for nirsevimab as first protective option for RSV in infants
January 5, 2023Medical Communications
The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease …
Island Pharmaceuticals to begin phase 2 trial for dengue prevention and treatment drug
January 5, 2023Research and Development
It is possible that Island Pharmaceuticals could begin its phase 2a PEACH clinical trial as soon as January 2023. The …
Belharra Therapeutics and Genentech join forces for small molecule medicine development
January 5, 2023Research and Development
US-based biotech companies Belharra Therapeutics and Genentech have announced a multi-year partnership to lead the discovery and development of small …
Biogen and Alcyone Therapeutics enter partnership to develop ThecaFlex DRx system for ASO therapies
January 5, 2023Research and Development
US-based Biogen and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System. …
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
January 4, 2023Business Services
Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
January 4, 2023Business Services
Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …
Dr Samson Fung
January 4, 2023Business Services
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing …
Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
January 4, 2023Business Services
London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …
FDA expands access to abortion pills
January 4, 2023Medical Communications
Following new rules from the FDA under the Biden administration, patients can now obtain the abortion pill mifepristone from retail …
Novartis pays $245m to settle Exforge generic pay-for-delay lawsuit
January 4, 2023Medical Communications
Swiss pharma company Novartis will settle a classic generic pay-for-delay legal battle with direct purchasers, indirect purchasers and retailers regarding …
FDA grants Breakthrough Device Designation for Burning Rock’s multi-cancer detecting test
January 4, 2023Medical Communications
Burning Rock, a Chinese biotech company which focuses on the applications of next-generation sequencing (NGS) technology in the field of …
FDA expected to make decision on controversial Alzheimer’s drug this week
January 4, 2023Medical Communications
The FDA are expected to come to a decision on Eisai and Biogen’s Alzheimer’s drug lecanemab by the end of …
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
January 3, 2023Business Services
Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
January 3, 2023Business Services
BEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a …
Cost of over 350 drugs expected to increase in 2023
January 3, 2023Sales and Marketing
With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation …
Rare cancer drug for young patients approved
January 3, 2023Research and Development
A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA …
MediWound receives FDA approval for NexoBrid
January 3, 2023Medical Communications
Israeli biopharma company MediWound has secured FDA approval for its wound care product NexoBrid (anacaulase-bcdb). US-based biopharma company Vericel will …
Datar blood test receives FDA Breakthrough Designation
January 3, 2023Medical Communications
Datar Cancer Genetics has secured FDA Breakthrough Designation for their blood test used to detect inaccessible brain tumours, where traditional …
BioNTech begins phase 1 trial for malaria vaccine
December 23, 2022Medical Communications
BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which …
